Announcements

Conference: 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Date: 14–18 July 2025
Location: Copenhagen, Denmark

MDPI will be attending the 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society as an exhibitor, welcoming researchers from diverse backgrounds to visit and share their latest ideas.

The 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society will be jointly hosted by the IEEE (Institute of Electrical and Electronics Engineers) and the IEEE Engineering in Medicine and Biology Society (EMBS). The overarching conference theme, “Engineering Medicine, Innovating Healthcare”, underscores the pivotal role of interdisciplinary collaboration and new ways of driving transformative advancements in healthcare delivery and patient outcomes.

We cordially invite you to join us as we embark on a journey to revolutionize healthcare through innovation, AI, and technology integration. We look forward to seeing you in Copenhagen in July 2025!

The following MDPI journals will be represented:

• Diagnostics;
• AI;
• BioMedInformatics;
• JCM;
• Biomimetics;
• Bioengineering;
• IJERPH;
• Diseases;
• Journal of Imaging;
• Sensors;
• Eng;
• Biosensors;
• MTI;
• Reports;
• Anatomia;
• Biomed;
• Surgical Techniques Development;
• Biotech;
• Signals;
• Tomography.

If you are planning to attend this conference, please do not hesitate to start an online conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information, please visit https://embc.embs.org/2025/.

We are pleased to announce that the 2024 Tu Youyou Award has been conferred upon Richard DiMarchi and Rolf Müller, in recognition of their significant contributions to natural products chemistry and medicinal chemistry.

Richard DiMarchi Indiana University, USA	Prof. Richard DiMarchi is a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University, USA. He is a member of the National Academy of Medicine and the National Inventors Hall of Fame. Dr. DiMarchi is a former Group Vice President at Eli Lilly and later at Novo Nordisk. He is recognized for his contributions to the discovery and development of rDNA-derived Humulin®, Humalog®, rGlucagon®, and Forteo®. His academic research has broadened the understanding of glucagon and incretin physiology and pioneered the discovery of single-molecule multi-mechanism agonists for the treatment of diabetes and obesity. The central element to success has been the chemical vision and technology to install within single molecules simultaneous agonism at related G-protein coupled receptors, coupled to the counter-intuitive discovery that glucagon and GIP agonism could synergize the therapeutic efficacy of GLP-1. These peptides and their conceptual approach have transformed the management of excessive body weight to a condition comparable to how hypertension, adult-onset diabetes, and excess cholesterol are medicinally managed.
“Professor DiMarchi was recognized by the 2024 Tu Youyou Award Committee members as being an exceptional leader in the medicinal chemistry of peptides and proteins of natural origin, and as a pioneer in the field of chemical biotechnology. His very important discoveries have led to breakthroughs in new drugs related to the therapy of diabetes and obesity. He has been named as an inventor on a very large number of patents, and he has had initially a highly successful scientific and administrative career in industry, which was followed by over two decades in academia as a distinguished professor.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee
Rolf Müller Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Germany; Helmholtz Centre for Infections Research (HZI), Germany; Saarland University, Germany	Prof. Rolf Müller is the Founding and Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Professor of Pharmaceutical Biotechnology at Saarland University, Germany. Having received his training from the University of Bonn, he held research positions at the University of Washington, USA, and Braunschweig University of Technology, Germany, prior to his appointment as professor to Saarland University. His laboratory has dedicated itself to the exploration of bacterial natural-product biosynthetic pathways for more than 20 years and has extensive experience in working with myxobacteria and other microbial producer strains. Starting from the isolation and characterization of new microorganisms, the scope of work includes microbiology-, biotechnology-, bioinformatics-, and chemistry-based approaches to exploit these isolates as sources of new drugs with a special focus on novel anti-infectives. Müller and his team apply a variety of state-of-the-art analytical methods and biological assays to perform biological and chemical characterizations of the identified compounds. Prof. Müller has received several awards, including the prestigious Gottfried Wilhelm Leibniz Prize, the PHOENIX Pharmacy Research Award, the DECHEMA Prize, and the Inhoffen Medal, as well as being an elected member of acatech, Leopoldina, and the German Academy of Sciences and Literature.
“The 2024 Tu Youyou Award Committee members were highly impressed by the truly outstanding past and ongoing contributions of Professor Müller in both microbial natural products isolation chemistry and in biosynthesis, as well as in the development of lead compounds for their potential in treating human diseases, through his global connections with various major funding agencies. He is also a dedicated teacher who has trained numerous graduate students and postdoctoral fellows, and he has lectured on his research in countries all over the world.” —Prof. Dr. A. Douglas Kinghorn, Chair of the Award Committee

The achievements of Richard DiMarchi and Rolf Müller highlight the transformative impact of natural products chemistry and medicinal chemistry. We congratulate them and invite the global academic community and public to join us in celebrating their significant contributions.

2024 Award Committee
Committee Chair:

• Prof. Dr. A. Douglas Kinghorn, Ohio State University, USA.
  

Committee Members (listed in alphabetical order):

• Prof. Angelo Fontana, University of Naples “Federico II”, Italy;
• Prof. Binghe Wang, Georgia State University, USA;
• Dr. Diana Pinto, University of Aveiro, Portugal;
• Prof. Hideaki Kakeya, Kyoto University, Japan;
• Dr. RuAngelie Edrada-Ebel, University of Strathclyde, UK;
• Prof. Thomas Prisinzano, University of Kentucky, USA
• Prof. Wei Li, University of Tennessee Health Science Center, USA.

About the Tu Youyou Award:
The 2024 Tu Youyou Award includes a total monetary prize of 100,000 Swiss Francs and a medal for each recipient. Established in 2016 to honor the pioneering spirit of Nobel laureate Tu Youyou, the Tu Youyou Award is an international award honoring exceptional scholars dedicated to the fields of natural products chemistry and medicinal chemistry.

For further information about the award and the winners, please visit the Tu Youyou Award website.

Dear Editorial Board Members, Guest Editors, Authors, and Reviewers,

It is with great pleasure that I share the news that Diagnostics (ISSN: 2075-4418) has received an increased Impact Factor of 3.3 for 2024 (JCR Q1, 57/332). Diagnostics also received an increased CiteScore of 5.9 (marking the fifth consecutive year of growth). This continued growth reflects your invaluable contributions, unwavering support, and commitment to scientific excellence.

I would like to extend my sincere gratitude to each of you for your dedication, insightful reviews, and high-quality submissions. Together, we have strengthened the journal’s visibility, scientific impact, and community.

I look forward to building further on this momentum and to our continued collaboration in the coming years.

Best regards,
Professor Andreas Kjaer
Editor-in-Chief, Diagnostics

We are pleased to share that the Diagnostics (ISSN: 2075-4418) was awarded an increased Impact Factor of 3.3 in the 2024 Journal Citation Reports™ released by Clarivate™ in June 2025. Diagnostics ranks in Q1 (57 among 332 titles) in the “Medicine, General and Internal” category. 

The 2024 Journal Impact Factor is calculated by dividing the number of citations received in 2024 to all publications in the journal from 2022 and 2023 by the total number of citable publications from those same years. 

To learn more, visit our journal statistics website for detailed metrics or check out our news article for general information. 

The support and dedication of all the editors, reviewers, authors, and readers are an integral part of the journal’s performance. We would like to take this opportunity to thank all of you who have contributed to the journal.

We are pleased to share that Diagnostics (ISSN: 2075-4418) has received an increased CiteScore of 5.9 in June 2025. The CiteScore ranks the journal 47 out of 171 titles (Q2) in the “Internal Medicine” category, and 45 out of 121 titles (Q2) in the “Clinical Biochemistry” category, an impressive achievement for a journal running in Volume 15.

You can find more statistics on our website. 

The current CiteScores measure the average number of citations within a journal over a four-year window (2021–2024). The Scopus database provides a comprehensive suite of metrics that support informed publishing strategies, research evaluation and enable benchmarking of journal performance. 

This achievement reflects the collective efforts of our authors, reviewers, and editors. Together we will continue to track the progress of Diagnostics and its growing impact in medical diagnosis research.

International Albinism Awareness Day 2025 underscores the urgent need for increased awareness, preventive care, and accessible healthcare for people with albinism. This year’s theme highlights the life-threatening impact of skin cancer among individuals with albinism and reinforces the importance of sun protection, early detection, and timely treatment.

Albinism is a rare, inherited genetic condition that affects the body’s ability to produce melanin, the pigment responsible for the color of our skin, hair, and eyes. People with albinism typically have very light skin and hair, alongside various vision impairments. While it is not contagious and does not affect intelligence, albinism is often misunderstood. This leads to stigmatization, discrimination, and even human rights violations in some regions where harmful myths persist.

Because they have little to no melanin, individuals with albinism are especially vulnerable to sun damage and face a significantly increased risk of developing skin cancer. Addressing this requires more than just clinical intervention—it calls for integrated healthcare policies and inclusive social systems that acknowledge both the medical and socio-political dimensions of the condition.

In recognition of this global observance, we invite you to explore a curated collection of articles and Special Issues from selected MDPI journals, including Biomedicines, Cancers, Children, Diagnostics, Genes, International Journal of Molecular Sciences, Journal of Clinical Medicine and Molecules. These open-access resources provide critical insights into the diagnosis, management, and complications of albinism, and promote cross-disciplinary collaboration between researchers, clinicians, and advocacy groups.

Together, through science, education, and empathy, we can foster a more inclusive world where people with albinism live free from discrimination and with access to the care they deserve.

“Can a Portable Flash Visual Evoked Potential (VEP) Device Identify Chiasmal Decussation Anomalies in Albinism?”
by Eloise Keeling, Perry Carter, Abdi Malik Musa, Fatima Shawkat, Helena Lee and Jay E. Self
Diagnostics 2025, 15(11), 1395; https://doi.org/10.3390/diagnostics15111395

“Common Variants in the TYR Gene with Unclear Pathogenicity as the Cause of Oculocutaneous Albinism in a Cohort of Russian Patients”
by Olga Shchagina, Anna Stepanova, Polina Mishakova, Vitaliy Kadyshev, Nina Demina, Ludmila Bessonova, Sofya Ionova, Daria Guseva, Andrey Marakhonov, Rena Zinchenko et al.
Biomedicines 2024, 12(10), 2234; https://doi.org/10.3390/biomedicines12102234

“Functional Characterization of Splice Variants in the Diagnosis of Albinism”
by Modibo Diallo, Cécile Courdier, Elina Mercier, Angèle Sequeira, Alicia Defay-Stinat, Claudio Plaisant, Shahram Mesdaghi, Daniel Rigden, Sophie Javerzat, Eulalie Lasseaux et al.
Int. J. Mol. Sci. 2024, 25(16), 8657; https://doi.org/10.3390/ijms25168657

“Genetic Linkage between CAPN5 and TYR Variants in the Context of Albinism and Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Absence: A Case Report”
by Mirjana Bjeloš, Ana Ćurić, Mladen Bušić, Benedict Rak and Biljana Kuzmanović Elabjer
Int. J. Mol. Sci. 2024, 25(12), 6442; https://doi.org/10.3390/ijms25126442

“Missing Heritability in Albinism: Deep Characterization of a Hungarian Albinism Cohort Raises the Possibility of the Digenic Genetic Background of the Disease”
by Nikoletta Nagy, Margit Pal, Jozsef Kun, Bence Galik, Peter Urban, Marta Medvecz, Beata Fabos, Alexandra Neller, Aliasgari Abdolreza, Judit Danis, Viktoria Szabo, Zhuo Yang, Stefanie Fenske, Martin Biel, Attila Gyenesei, Eva Adam and Marta Szell
Int. J. Mol. Sci. 2024, 25(2), 1271; https://doi.org/10.3390/ijms25021271

“Does Foveal Hypoplasia Affect Emmetropization in Patients with Albinism?”
by Line Kessel, Christine Dahlgren Bohnsack Kjølholm and Joaquim Torner Jordana
Children 2023, 10(12), 1910; https://doi.org/10.3390/children10121910

“Vision-Related Quality of Life in Danish Patients with Albinism and the Impact of an Updated Optical Rehabilitation”
by Kristian Lisbjerg, Joaquim Torner Jordana, Vibeke N. Brandt, Christine Kjølholm and Line Kessel
J. Clin. Med. 2023, 12(17), 5451; https://doi.org/10.3390/jcm12175451

“Skin Pigmentation Types, Causes and Treatment—A Review”
by Amin Mahmood Thawabteh, Alaa Jibreen, Donia Karaman, Alà Thawabteh and Rafik Karaman
Molecules 2023, 28(12), 4839; https://doi.org/10.3390/molecules28124839

“Report of Hermansky–Pudlak Syndrome in Two Families with Novel Variants in HPS3 and HPS4 Genes”
by Sadeeda Qaiser Zaman, Muhammad Anas, Gauhar Rehman, Qadeem Khan, Aiman Iftikhar, Mashal Ahmad, Muhammad Owais, Ilyas Ahmad, Osama Yousef Muthaffar, Angham Abdulrhman Abdulkareem et al.
Genes 2023, 14(1), 145; https://doi.org/10.3390/genes14010145

“Diagnostic Yield of Genetic Testing for Ocular and Oculocutaneous Albinism in a Diverse United States Pediatric Population”
by Kyle S. Chan, Brenda L. Bohnsack, Alexander Ing, Andy Drackley, Valerie Castelluccio, Kevin X. Zhang, Hanta Ralay-Ranaivo and Jennifer L. Rossen
Genes 2023, 14(1), 135; https://doi.org/10.3390/genes14010135

“More than Skin Deep—Latest Advances in Congenital and Autoimmune Pigmentation Disorders” Guest Editor: Prof. Dr. Reinhart M. Speeckaert Submission deadline: 25 August 2025	“Melanin Pigmentation: Physiology and Pathology” Guest Editors: Prof. Dr. Shosuke Ito and Prof. Dr. Manickam Sugumaran Submission deadline: 20 October 2025

Conference: 34th International Congress—Science of Paediatric and Neonatal Intensive Care (ESPNIC 2025)
Date: 25–28 June 2025
Location: Alicante, Spain

We are pleased to announce that MDPI will participate in the 34th International Congress—Science of Paediatric and Neonatal Intensive Care (ESPNIC 2025), to be held in Alicante, Spain, from 25 to 28 June 2025.

The European Society for Paediatric and Neonatal Intensive Care (ESPNIC) is the world’s premier society dedicated to paediatric and neonatal critical care medicine. It is one of the oldest and largest paediatric scientific societies in Europe, and the only one exclusively focused on critical care for the most seriously ill children—those affected by complex disorders requiring vital support, advanced techniques, and multidisciplinary emergency management.

MDPI is excited to participate in this prestigious event! Representing the journal of Children (ISSN: 2227-9067), Ms. Ivana Marković and Mr. Emil-Gabriel Nutu will be present at the MDPI exhibition stand, where they will warmly welcome all scholars to stop by and engage in insightful discussions. This event presents a unique opportunity for participants to interact with leading experts in the field and explore potential collaborations. Do not miss the chance to visit our stand and exchange ideas with the MDPI editors and other delegates!

The following open access journals will be represented at the conference:

• Neurology International;
• Reports;
• Paediatric Reports;
• Diagnostics;
• Children;
• International Journal of Environmental Research and Public Health;
• Journal of Clinical Medicine;
• Nursing Reports;
• Clinics and Practice;
• Antibiotics;
• Neuroglia;
• Healthcare;
• Hygiene;
• Cardiogenetics;
• Advances in Respiratory Medicine;
• Journal of Respiration;
• Therapeutics;
• Nutrients;
• Emergency Care and Medicine;
• Surgical Techniques Development.

If you are planning to attend the conference, please feel free to start a conversation with us. We invite all conference attendees to visit MDPI’s booth and meet with our esteemed Editorial Board Members.

For more information about the conference, please visit the following website: https://www.mcascientificevents.eu/espnic/.

MDPI will be attending the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases, taking place from 26 to 30 May 2025 in Bucharest, Romania.

The 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases will be held in person in Bucharest and online. This premier meeting brings together leading researchers and specialists from across Europe and beyond, all committed to advancing the study, treatment, and prevention of infectious diseases in children.

The following MDPI journals will be represented at the conference:

• Pediatric Reports;
• Children;
• Diagnostics;
• Hygiene;
• Metabolites;
• Antibiotics;
• TropicalMed.

If you plan to attend the conference, we encourage you to visit our booth and speak to our representatives. We are eager to meet you in person and assist you with any queries that you may have.

For more information about the conference, please visit the official website at https://espidmeeting.org/.

Conference: The 34th Annual Meeting of the Japan Federation of Gerontological Societies
Organization: Japan Federation of Gerontological Societies
Date: 27–29 June 2025
Place: Chiba, Japan

MDPI journals will be present as exhibitors at the 34th Annual Meeting of the Japan Federation of Gerontological Societies, which will be held at Makuhari Messe, Chiba, Japan, from 27 to 29 June 2025. The conference will be led by the “Japan Federation of Gerontological Societies" and co-organized by seven related societies. The aging rate in Japan exceeded 28 percent in 2018, and only the age group of 75 or older will increase in the future; by 2040, one in four people is expected to be over 75. In this unprecedented context of growing aging, leading institutes in Japan are comprehensively addressing issues such as Alzheimer's disease and homelessness. The importance of the Japan Federation of Gerontological Societies as a collection of multiple societies is increasing due to the country becoming super-aged; moreover, the problems of the elderly cannot be solved by a single field such as medical dentistry nursing, biology, or social sciences. The conference is held every two years, and the official website of the societies can be found at the following link: https://geront.jp/en/index.html.

The following MDPI journals will be represented:

• Geriatrics;
• IJERPH;
• Healthcare;
• Nursing Reports;
• Diagnostics.

If you will be attending this conference, please feel free to visit our booth while you are there. Our delegates look forward to meeting you in person and answering any questions that you may have.